Professor Jacob George is a renowned hepatologist and liver research scientist who studies the causes of and mechanisms for the development of liver disease and liver cancer. He contributes to investigator-initiated and multicentre international clinical trials on therapeutics for liver diseases, and leads a program of research on viral hepatitis, fatty liver disease, liver fibrosis, host genetics/liver immunology and the epidemiology, prevention and management of liver cancer. His research has a strong translational component, linking laboratory and clinical research.
Professor George’s work has made significant contributions to clinical practice. His team first identified the role of interferon lambda 3 gene polymorphisms for predicting treatment response in chronic hepatitis C. These discoveries are considered major advances in the field and the finest examples of ‘personalised medicine’. Professor George was an author on the groundbreaking study of combination telaprevir, pegylated interferon and ribavirin therapy for hepatitis C, which changed the landscape of hepatitis C treatments, heralding the era of direct-acting
antivirals. He has over 340 publications and his work has been cited more than 25,000 times.